BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Bio-Pharm expands clinical pipelines aiming for IPO

March 27, 2020 | News

Bio-Pharm Solutions is currently planning to capitalize through an IPO to advance other clinical development projects



South Korea based Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease.

Based on the performance of its first pipeline, an infantile spasms drug, BIo-Pharm Solutions is currently planning to capitalize through an IPO to advance other clinical development projects.

Bio-Pharm Solutions' first pipeline, 'JBPOS0101,' is a drug for infantile spasms.

The safety study of JBPOS0101 was conducted under US FDA IND and has been confirmed through the phase 1 clinical trial in Canada. It received approval for the phase 2 clinical trial in the US (April) and in Korea (November) last year. The clinical trial is currently underway.

JBPOS0101 controls the occurrence of spasms directly and indirectly and it works on the mGluR family receptor, and also other unknown multiple mechanism. Unlike other existing drugs, it directly works on the ion channel related to the mode of action, and as a result, it has a low probability of developing tolerance and has a wider therapeutic coverage, according to BIo-Pharm Solutions.

In 2017, JBPOS0101 was approved for the Orphan Drug Designation (ODD) program by the US FDA.

Bio-Pharm Solutions' second pipeline is a Status epilepticus (SE) drug which is currently in the phase 1 clinical trial (intravenous injection toxicity study) in the US. It obtained ODD status from the US FDA in 2016.

While the Infantile spasms drug is administered orally, the Status epilepticus (SE) drug works via intravenous injection.

In addition, Bio-Pharm Solutions is planning to develop an oral medication for Alzheimer's disease through a new clinical pipeline. Currently, the company has completed the pre-clinical studies and will enter the phase 2 clinical trial in the US this year. "We have confirmed that our epilepsy drug candidate prevents the death of neurons in neurodegenerative diseases like Alzheimer's disease and also reduces tau and amyloid ?," said Dr. Choi. "We expect it will work for Alzheimer's disease, Parkinson's disease and certain pains."